Seeking Alpha

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
Seeking Alpha

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...
Nasdaq

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...
MarketWatch

New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX(R) Test on Patient Care and Healthcare Efficiency

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...
Business Insider

NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom

REDWOOD CITY, Calif., Dec. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has ...
News Medical

Oncotype DX Breast Recurrence Score test recommended by NICE for lymph node-positive breast cancer patients

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
CURE

From Diagnosis to Decision: How Guerdy Abraira Used Genomic Testing to Navigate Breast Cancer

Following her breast cancer diagnosis, Guerdy Abraira utilized genomic testing to gain clarity on her treatment path. For ...
WESA

Breast Cancer Gene Test Helps Predict Who Can Skip Chemo

For the past 10 years, doctors have used a genetic test to decide which patients may be able to skip chemotherapy after surgery for breast cancer. Now a study confirms that this test, called Oncotype ...
Business Insider

Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

REDWOOD CITY, Calif., Oct. 22, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX ® tests highlighting their value in optimizing ...
elEconomista

The Oncotype DX® Test and PrecisionOncology: New Data Presented at ESMO Further Demonstrate Genomic Health?s Successful Approach to Understanding Tumour Biology

In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress - ‘Precision Medicine in Cancer Care’ - Genomic Health presented results from multiple studies ...
ascopubs.org

Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Medscape

Multigene Predictors in Early-stage Breast Cancer: Moving in or Moving out?

At first glance, given that the two assays share only one overlapping gene, it would appear that the two assays have little in common in terms of genomic content. However, the priority gene lists are ...